
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
MYO1E (myosin IE) encodes a class I unconventional myosin that functions as an actin-based molecular motor. The protein contains a motor domain and a long tail domain capable of interacting with actin filaments. MYO1E contributes to intracellular movement, actin organization, and membrane trafficking, supporting cellular processes that depend on actin-based transport and cytoskeletal dynamics.
143B is a human osteosarcoma cell line derived indirectly from the HOS osteosarcoma cell line. The cells are deficient in thymidine kinase (TK−) and resistant to bromodeoxyuridine (BUdR). 143B is used as a model for studying osteosarcoma biology, tumor metabolism, and genetic selection systems involving thymidine kinase deficiency.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_004998
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?